NCT02026505

Evaluation of Cardiotoxic Effects of Bortezomib

Prospective Assessment of the Cardiac Effects the Proteasome Inhibitor Bortezomib in Patients Undergoing Therapy for Multiple Myeloma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 11 (actual)
• Sponsor: Oregon Health and Science University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart. In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here. The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.

Conditions

• Multiple Myeloma
• Heart Failure, Systolic
• Cardiotoxins

Interventions

Type	Name	Description
DRUG	Bortezomib

Timeline

• Start date: 2014-03-01
• Primary completion: 2016-12-31
• Completion: 2019-03-01
• First posted: 2014-01-03
• Last updated: 2019-03-13